{"product_id":"cardiac-biomarkers-market-global-industry-trends-share-size-growth-opportunity-and-forecast-2023-2028","title":"Cardiac Biomarkers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028","description":"\u003cp\u003eCardiac Biomarkers Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028\u003c\/p\u003e\n\n\u003cp\u003eThe global cardiac biomarkers market size reached US$ 9.8 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 16.2 Billion by 2028, exhibiting a growth rate (CAGR) of 8.42% during 2023-2028.\u003c\/p\u003e\n\n\u003cp\u003eCardiac markers, also known as cardiac biomarkers, are released into the bloodstream when the heart is stressed, or its muscles are damaged. These markers include different types of enzymes, hormones, and proteins, such as cardiac troponins, creatine kinase (CK), ischemia-modified albumin (IMA), and myoglobin. Measurement and testing of these markers can help in diagnosing heart conditions like cardiac ischemia and acute coronary syndrome (ACS). At present, the triage and diagnostic systems used for determining the risk of these conditions are based on electrocardiograms (ECGs) and clinical history. However, these systems are insufficient and can lead to misdiagnosis or delay in treatment. As cardiac marker testing offers higher accuracy and can identify the conditions in the early stages of presentation, they are gaining traction across the globe. These markers can also help in monitoring the prognosis of these condition with greater accuracy and providing the most effective treatment to the patients.\u003c\/p\u003e\n\n\u003cp\u003eGlobal Cardiac Biomarkers Market Drivers:\u003cbr\u003e\nOver the past few years, there has been a rise in the number of patients suffering from ACS which has created a demand for cardiac marker testing at a global level. Other than this, rising awareness among patients and healthcare providers about the importance of early diagnosis of various CVDs is driving the demand for these markers. In addition, there are numerous private and public organizations which are investing in R\u0026amp;D activities to develop advanced technologies in the field of cardiac biomarkers. For instance, blood tests for high-sensitivity cardiac troponin I have been demonstrated to identify patients who are at a higher risk of a second heart attack. Moreover, high accuracy and rapid results offered by biomarker testing, coupled with the availability of affordable cardiac point-of-care testing, are some of the other factors which are contributing to the growth of the market.\u003c\/p\u003e\n\n\u003cp\u003eKey Market Segmentation:\u003cbr\u003e\nIMARC Group provides an analysis of the key trends in each sub-segment of the global cardiac biomarkers market report, along with forecasts at the global and regional level from 2023-2028. Our report has categorized the market based on type, location of testing, and application.\u003c\/p\u003e\n\n\u003cp\u003eBreakup by Type:\u003c\/p\u003e\n\n\u003cp\u003eTroponins (T and I) \u003cbr\u003e\nMyocardial Muscle Creatine Kinase (CK-MB)\u003cbr\u003e\nMyoglobin\u003cbr\u003e\nBrain Natriuretic Peptide (BNPs) or NT-proBNP \u003cbr\u003e\nIschemia Modified Albumin (IMA) \u003cbr\u003e\nOthers\u003cbr\u003e\n \u003cbr\u003e\nBased on the type, the market has been segmented into troponins (T and I), myocardial muscle creatine kinase (CK-MB), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, ischemia modified albumin (IMA) and others.\u003c\/p\u003e\n\n\u003cp\u003eBreakup by Location of Testing:\u003c\/p\u003e\n\n\u003cp\u003eLaboratory Testing \u003cbr\u003e\nPoint of Care Testing\u003cbr\u003e\n \u003cbr\u003e\nBased on the location of testing, the market has been segmented into laboratory testing and point of care testing. Laboratory testing currently accounts for a larger share.\u003c\/p\u003e\n\n\u003cp\u003eBreakup by Application:\u003c\/p\u003e\n\n\u003cp\u003eMyocardial Infarction\u003cbr\u003e\nCongestive Heart Failure\u003cbr\u003e\nAcute Coronary Syndrome\u003cbr\u003e\nAtherosclerosis\u003cbr\u003e\nOthers\u003cbr\u003e\n \u003cbr\u003e\nBased on the application, the market has been segmented into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis and others. Myocardial infarction currently accounts for the highest share.\u003c\/p\u003e\n\n\u003cp\u003eRegional Insights:\u003c\/p\u003e\n\n\u003cp\u003eNorth America\u003cbr\u003e\nAsia Pacific\u003cbr\u003e\nEurope\u003cbr\u003e\nMiddle East and Africa\u003cbr\u003e\nLatin America\u003cbr\u003e\n \u003cbr\u003e\nRegion-wise, the market has been segmented into North America, Asia Pacific, Europe, Middle East and Africa, and Latin America. Amongst these, North America is the biggest market, accounting for majority of the global share.\u003c\/p\u003e\n\n\u003cp\u003eCompetitive Landscape:\u003cbr\u003e\nThe report has also analyzed the competitive landscape of the market with some of the key players being Abbott Laboratories, Alere Inc., Beckman Coulter, Becton, Dickinson And Co., Biomerieux, Bio-Rad Laboratories, Randox Laboratories, Roche Diagnostics Corporation, Siemens Healthcare and Thermo Fisher Scientific.\u003c\/p\u003e\n\n\u003cp\u003eKey Questions Answered in This Report\u003cbr\u003e\n1. What was the size of the global cardiac biomarkers market in 2022?\u003cbr\u003e\n2. What is the expected growth rate of the global cardiac biomarkers market during 2023- 2028?\u003cbr\u003e\n3. What are the key factors driving the global cardiac biomarkers market?\u003cbr\u003e\n4. What has been the impact of COVID-19 on the global cardiac biomarkers market?\u003cbr\u003e\n5. What is the breakup of the global cardiac biomarkers market based on the location of testing?\u003cbr\u003e\n6. What is the breakup of the global cardiac biomarkers market based on the application?\u003cbr\u003e\n7. What are the key regions in the global cardiac biomarkers market?\u003cbr\u003e\n8. Who are the key companies\/players in the global cardiac biomarkers market?\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"January, 2023 \/ 112 Pages \/ MCW16226366","offer_id":47640131273010,"sku":null,"price":2999.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/cardiac-biomarkers-market-global-industry-trends-share-size-growth-opportunity-and-forecast-2023-2028","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}